Last patient completes treatment in RP101 Phase II clinical trial
Redwood Pharma can today report that the last patient received their last dose in the company's Phase II trial of RP101, a treatment for chronic dry eye syndrome in post-menopausal women. Thus, the treatment phase in the clinical trial is finished.This milestone will now be followed by an intensive period in which all data from the participating clinics will be compiled and analyzed. Extensive work on data compilation and processing will continue in the coming months. In line with what has been previously communicated, management's assessment is that topline results will be published during